NORWALK, Conn., July 29, 2024 — The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Envisagenics, a biotechnology company at the forefront of RNA splicing technology.
“The potential of its innovative RNA-based platform and A.I.-fueled technology could pave the way for promising new treatments for the myeloma community,” said Michael Andreini, President and CEO at the Multiple Myeloma Research Foundation.
Utilizing advanced artificial intelligence and machine learning, Envisagenics is discovering and developing novel RNA-based therapeutics to address critical unmet need in multiple myeloma.
“In multiple myeloma, aberrant RNA splicing leads to the production of disease-specific epitopes that can be used as drug targets, allowing for targeted elimination of cancer cells while sparing healthy cells. At Enivsagenics, we are leveraging our SpliceCore platform, which combines a proprietary database of 14 million splicing events with A.I. and machine learning to identify multiple myeloma-specific targets to develop novel immunotherapies,” said Maria Luisa Pineda, Ph.D., co-founder and CEO of Envisagenics. “We are pleased to welcome the Myeloma Investment Fund and the Multiple Myeloma Research Foundation as investors. Their extensive network and scientific expertise will enable us to accelerate the discovery and development of novel treatments specifically tailored to multiple myeloma and other cancers.”
About the Myeloma Investment Fund (MIF)
The Myeloma Investment Fund is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit www.myelomainvestmentfund.org
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $600 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org
For MMRF or MIF media inquiries, please contact: Anna Otis, Manager, Brand Marketing, [email protected]
